Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

Egyptian Rousette Bat Genome Provides Clues to Antiviral Mystery

Friday, July 13, 2018

When humans are infected with the Marburg virus, the result is often lethal, with hemorrhagic fever and other symptoms similar to Ebola. When bats are infected, the result is…. nothing. The tiny mammals remain asymptomatic.

In order to crack this antiviral mystery, a multi-institutional team of scientists sequenced, assembled and analyzed the genome of the bat species Rousettus aegyptiacus, a natural reservoir of Marburg virus and the only known reservoir for any filovirus.

Their findings contradicted previous hypotheses about bat antiviral immunity, which assumed  that bats had enhanced antiviral defenses, controlling viral replication early in infection, and developing effective adaptive immune responses as a result. The new analysis suggests that an inhibitory immune state may exist instead.

Led by Boston University researchers Thomas B. Kepler and Stephanie S. Pavlovich, with Gustavo Palacios of the United States Army Research Institute of Infectious Diseases and others from Columbia University, the University of Nebraska, the NIH’s National Center for Biotechnology Information, and the Viral Special Pathogens Branch of the Centers for Disease Control and Prevention, the study in Cell describes several differences between immune responses in bats and humans.

Among them was an expanded and diversified KLRC/KLRD family of natural killer cell receptors, MHC class I genes, and type I interferons in the bats, which dramatically differ from their functional counterparts in other mammals.

“Such concerted evolution of key components of bat immunity is strongly suggestive of novel modes of antiviral defense,” the authors write.

The stark difference between bat and primate antiviral responses has long motivated scientists to characterize the genes involved in the immune system of bats, but previous efforts relied on genomes generated with low-coverage sequencing or with only short-read sequencing technologies. Such assemblies limit the ability to resolve repetitive regions of the genome where important immune gene loci reside, the authors note. So they turned to PacBio long-read sequencing, combined with paired-end short-reads, to generate a high-quality annotated genome for the Egyptian rousette bat. The result is a 1.91 Gb Raegyp2.0 genome, the most contiguous bat genome available.

Natural Killers

Bat genome

They used the genome to study two large classes of immune genes: natural killer (NK) cell receptors and type I interferons (IFNs). Previous studies have reported the absence of canonical NK cell receptors in bat genomes, and others have suggested that significant differences exist in type I IFNs between bats and humans. Diving deeper, the new study found an unusual expansion of the KLRC (NKG2) and KLRD (CD94) gene families in R. aegyptiacus relative to other species, “showing genomic evidence of unique features and expression of these receptors that may result in a net inhibitory balance within bat NK cells.”

“The expansion of NK cell receptors is matched by an expansion of potential MHC class I ligands, which are distributed both within and, surprisingly, outside the canonical MHC loci,” the authors note.

They also observed that the type I IFN locus is considerably expanded and diversified in R. aegyptiacus, with members of the IFN-u subfamily being induced after viral infection and showing antiviral activity.

“All these features strengthen the notion of the unique biology of bats and suggest the existence of a distinct immunomodulatory mechanism used to control viral infection,” the authors conclude.

“Our findings are consistent with the hypothesis that certain key components of the immune system in bats have coevolved with viruses toward a state of respective tolerance and avirulence, although tolerance is likely not the only mechanism at play.”

The team notes that definitive tests of their hypotheses may be possible with the development of further experimental reagents for cytometry and biochemical intervention, and that such reagents are being developed now with information made available by the completed genome project.

And while the genome for R. aegyptiacus is providing useful information about how bats resist viral infections, it is just one species of interest to scientists who would like to better understand the genetics of bats in order to shed light on human and ecological biology. The Bat1K initiative is an effort by more than 140 scientists around the world to decode the genomes of all 1,300 species of bats using SMRT Sequencing and other technologies.

Subscribe for blog updates: